WuXi XDC Cayman Inc

2268.HK | Healthcare | HKSE
$70.85
+0.55 (+0.78%)

Key Metrics

Market Cap
$85.25B
P/E Ratio
63.83
EPS
$1.11
Beta
N/A
Dividend Yield
N/A
ROE
18.85%
Current Ratio
2.20

Company Information

Industry
Medical Diagnostics Research

About WuXi XDC Cayman Inc

WuXi XDC Cayman Inc an investment holding company operates as a contract research development and manufacturing organization in China North America Europe and internationally It engages in the discovery research development and manufacture of antibody drug conjugates bioconjugates monoclonal antibody intermediates and payloadlinkers associated with bioconjugates The company was founded in 2013 and is headquartered in Wuxi China WuXi XDC Cayman Inc operates as a subsidiary of WuXi Biologics Cayman Inc

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-08-20 $0.57 $0.61 -6.6%
2025-03-25 $0.52 $0.48 +9.0%
2024-08-20 $0.38 $0.25 +53.7%
2024-03-25 $0.12 $0.11 +10.0%

Financial Ratios (TTM)

Gross Margin
33.01%
Operating Margin
25.44%
Net Margin
26.08%
ROA
12.49%
Price to Book
11.56
Price to Sales
15.55